Browsing by Subject "histamine H1 receptor antagonist"

Now showing 1 - 6 of 6
  • No Thumbnail Available
    Item
    Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA2LEN and AllerGen)
    (Blackwell Publishing Ltd, 2008) Bousquet J.; Khaltaev N.; Cruz A.A.; Denburg J.; Fokkens W.J.; Togias A.; Zuberbier T.; Baena-Cagnani C.E.; Canonica G.W.; Van Weel C.; Agache I.; Aït-Khaled N.; Bachert C.; Blaiss M.S.; Bonini S.; Boulet L.-P.; Bousquet P.-J.; Camargos P.; Carlsen K.-H.; Chen Y.; Custovic A.; Dahl R.; Demoly P.; Douagui H.; Durham S.R.; Van Wijk R.G.; Kalayci O.; Kaliner M.A.; Kim Y.-Y.; Kowalski M.L.; Kuna P.; Le L.T.T.; Lemiere C.; Li J.; Lockey R.F.; Mavale-Manuel S.; Meltzer E.O.; Mohammad Y.; Mullol J.; Naclerio R.; O'Hehir R.E.; Ohta K.; Ouedraogo S.; Palkonen S.; Papadopoulos N.; Passalacqua G.; Pawankar R.; Popov T.A.; Rabe K.F.; Rosado-Pinto J.; Scadding G.K.; Simons F.E.R.; Toskala E.; Valovirta E.; Van Cauwenberge P.; Wang D.-Y.; Wickman M.; Yawn B.P.; Yorgancioglu A.; Yusuf O.M.; Zar H.; Annesi-Maesano I.; Bateman E.D.; Kheder A.B.; Boakye D.A.; Bouchard J.; Burney P.; Busse W.W.; Chan-Yeung M.; Chavannes N.H.; Chuchalin A.; Dolen W.K.; Emuzyte R.; Grouse L.; Humbert M.; Jackson C.; Johnston S.L.; Keith P.K.; Kemp J.P.; Klossek J.-M.; Larenas-Linnemann D.; Lipworth B.; Malo J.-L.; Marshall G.D.; Naspitz C.; Nekam K.; Niggemann B.; Nizankowska-Mogilnicka E.; Okamoto Y.; Orru M.P.; Potter P.; Price D.; Stoloff S.W.; Vandenplas O.; Viegi G.; Williams D.
    [No abstract available]
  • No Thumbnail Available
    Item
    Allergic rhinitis and its impact on asthma update (ARIA 2008): The Turkish perspective
    (2008) Kalayci Ö.; Yorgancioǧlu A.; Kalyoncu A.F.; Khaltaev N.; Bousquet J.
    Allergic rhinitis is a symptomatic disorder of the nose induced after allergen exposure due to an IgE-mediated inflammation of the membranes lining the nose. According to its definition in 1929, "The three cardinal symptoms in nasal reactions occurring in allergy are sneezing, nasal obstruction and mucous discharge." Allergic rhinitis is a global health problem. Patients from all countries, ethnic groups, and ages suffer from allergic rhinitis. Allergic rhinitis causes major illness and disability worldwide. It affects social life, sleep, school and work. The economic impact of allergic rhinitis is substantial; however, rhinitis is still underdiagnosed and undertreated.
  • No Thumbnail Available
    Item
    Allergic Rhinitis and its Impact on Asthma (ARIA): Achievements in 10 years and future needs
    (2012) Bousquet J.; Schünemann H.J.; Samolinski B.; Demoly P.; Baena-Cagnani C.E.; Bachert C.; Bonini S.; Boulet L.P.; Bousquet P.J.; Brozek J.L.; Canonica G.W.; Casale T.B.; Cruz A.A.; Fokkens W.J.; Fonseca J.A.; Van Wijk R.G.; Grouse L.; Haahtela T.; Khaltaev N.; Kuna P.; Lockey R.F.; Lodrup Carlsen K.C.; Mullol J.; Naclerio R.; O'hehir R.E.; Ohta K.; Palkonen S.; Papadopoulos N.G.; Passalacqua G.; Pawankar R.; Price D.; Ryan D.; Simons F.E.R.; Togias A.; Williams D.; Yorgancioglu A.; Yusuf O.M.; Aberer W.; Adachi M.; Agache I.; Aït-Khaled N.; Akdis C.A.; Andrianarisoa A.; Annesi-Maesano I.; Ansotegui I.J.; Baiardini I.; Bateman E.D.; Bedbrook A.; Beghé B.; Beji M.; Bel E.H.; Ben Kheder A.; Bennoor K.S.; Bergmann K.C.; Berrissoul F.; Bieber T.; Bindslev Jensen C.; Blaiss M.S.; Boner A.L.; Bouchard J.; Braido F.; Brightling C.E.; Bush A.; Caballero F.; Calderon M.A.; Calvo M.A.; Camargos P.A.M.; Caraballo L.R.; Carlsen K.H.; Carr W.; Cepeda A.M.; Cesario A.; Chavannes N.H.; Chen Y.Z.; Chiriac A.M.; Chivato Pérez T.; Chkhartishvili E.; Ciprandi G.; Costa D.J.; Cox L.; Custovic A.; Dahl R.; Darsow U.; De Blay F.; Deleanu D.; Denburg J.A.; Devillier P.; Didi T.; Dokic D.; Dolen W.K.; Douagui H.; Dubakiene R.; Durham S.R.; Dykewicz M.S.; El-Gamal Y.; El-Meziane A.; Emuzyte R.; Fiocchi A.; Fletcher M.; Fukuda T.; Gamkrelidze A.; Gereda J.E.; González Diaz S.; Gotua M.; Guzmán M.A.; Hellings P.W.; Hellquist-Dahl B.; Horak F.; Hourihane J.O'B.; Howarth P.; Humbert M.; Ivancevich J.C.; Jackson C.; Just J.; Kalayci O.; Kaliner M.A.; Kalyoncu A.F.; Keil T.; Keith P.K.; Khayat G.; Kim Y.Y.; Koffi N'Goran B.; Koppelman G.H.; Kowalski M.L.; Kull I.; Kvedariene V.; Larenas-Linnemann D.; Le L.T.; Lemière C.; Li J.; Lieberman P.; Lipworth B.; Mahboub B.; Makela M.J.; Martin F.; Marshall G.D.; Martinez F.D.; Masjedi M.R.; Maurer M.; Mavale-Manuel S.; Mazon A.; Melen E.; Meltzer E.O.; Mendez N.H.; Merk H.; Mihaltan F.; Mohammad Y.; Morais-Almeida M.; Muraro A.; Nafti S.; Namazova-Baranova L.; Nekam K.; Neou A.; Niggemann B.; Nizankowska-Mogilnicka E.; Nyembue T.D.; Okamoto Y.; Okubo K.; Orru M.P.; Ouedraogo S.; Ozdemir C.; Panzner P.; Pali-Schöll I.; Park H.S.; Pigearias B.; Pohl W.; Popov T.A.; Postma D.S.; Potter P.; Rabe K.F.; Ratomaharo J.; Reitamo S.; Ring J.; Roberts R.; Rogala B.; Romano A.; Roman Rodriguez M.; Rosado-Pinto J.; Rosenwasser L.; Rottem M.; Sanchez-Borges M.; Scadding G.K.; Schmid-Grendelmeier P.; Sheikh A.; Sisul J.C.; Solé D.; Sooronbaev T.; Spicak V.; Spranger O.; Stein R.T.; Stoloff S.W.; Sunyer J.; Szczeklik A.; Todo-Bom A.; Toskala E.; Tremblay Y.; Valenta R.; Valero A.L.; Valeyre D.; Valiulis A.; Valovirta E.; Van Cauwenberge P.; Vandenplas O.; Van Weel C.; Vichyanond P.; Viegi G.; Wang D.Y.; Wickman M.; Wöhrl S.; Wright J.; Yawn B.P.; Yiallouros P.K.; Zar H.J.; Zernotti M.E.; Zhong N.; Zidarn M.; Zuberbier T.; Ang C.S.; Baigenzhin A.K.; Boakye D.A.; Briggs A.H.; Burney P.G.; Busse W.W.; Chuchalin A.G.; Haddad H.; Johnston S.L.; Kogevinas M.; Levy M.L.; Mohammadi A.; Oddie S.; Rezagui D.; Terreehorst I.; Warner J.O.
    Allergic rhinitis (AR) and asthma represent global health problems for all age groups. Asthma and rhinitis frequently coexist in the same subjects. Allergic Rhinitis and its Impact on Asthma (ARIA) was initiated during a World Health Organization workshop in 1999 (published in 2001). ARIA has reclassified AR as mild/moderate-severe and intermittent/persistent. This classification closely reflects patients' needs and underlines the close relationship between rhinitis and asthma. Patients, clinicians, and other health care professionals are confronted with various treatment choices for the management of AR. This contributes to considerable variation in clinical practice, and worldwide, patients, clinicians, and other health care professionals are faced with uncertainty about the relative merits and downsides of the various treatment options. In its 2010 Revision, ARIA developed clinical practice guidelines for the management of AR and asthma comorbidities based on the Grading of Recommendation, Assessment, Development and Evaluation (GRADE) system. ARIA is disseminated and implemented in more than 50 countries of the world. Ten years after the publication of the ARIA World Health Organization workshop report, it is important to make a summary of its achievements and identify the still unmet clinical, research, and implementation needs to strengthen the 2011 European Union Priority on allergy and asthma in children. © 2012 American Academy of Allergy, Asthma & Immunology.
  • No Thumbnail Available
    Item
    Treatment of allergic rhinitis using mobile technology with real-world data: The MASK observational pilot study
    (Blackwell Publishing Ltd, 2018) Bousquet J.; Devillier P.; Arnavielhe S.; Bedbrook A.; Alexis-Alexandre G.; van Eerd M.; Murray R.; Canonica G.W.; Illario M.; Menditto E.; Passalacqua G.; Stellato C.; Triggiani M.; Carreiro-Martins P.; Fonseca J.; Morais Almeida M.; Nogueira-Silva L.; Pereira A.M.; Todo Bom A.; Bosse I.; Caimmi D.; Demoly P.; Fontaine J.F.; Just J.; Onorato G.L.; Kowalski M.L.; Kuna P.; Samolinski B.; Anto J.M.; Mullol J.; Valero A.; Tomazic P.V.; Bergmann K.C.; Keil T.; Klimek L.; Mösges R.; Shamai S.; Zuberbier T.; Murphy E.; McDowall P.; Price D.; Ryan D.; Sheikh A.; Chavannes N.H.; Fokkens W.J.; Kvedariene V.; Valiulis A.; Bachert C.; Hellings P.W.; Kull I.; Melen E.; Wickman M.; Bindslev-Jensen C.; Eller E.; Haahtela T.; Papadopoulos N.G.; Annesi-Maesano I.; Bewick M.; Bosnic-Anticevich S.; Cruz A.A.; De Vries G.; Gemicioglu B.; Larenas-Linnemann D.; Laune D.; Mathieu-Dupas E.; O'Hehir R.E.; Pfaar O.; Portejoie F.; Siroux V.; Spranger O.; Valovirta E.; VandenPlas O.; Yorgancioglu A.
    Background: Large observational implementation studies are needed to triangulate the findings from randomized control trials as they reflect “real-world” everyday practice. In a pilot study, we attempted to provide additional and complementary insights on the real-life treatment of allergic rhinitis (AR) using mobile technology. Methods: A mobile phone app (Allergy Diary, freely available in Google Play and Apple App stores) collects the data of daily visual analog scales (VAS) for (i) overall allergic symptoms, (ii) nasal, ocular, and asthma symptoms, (iii) work, as well as (iv) medication use using a treatment scroll list including all medications (prescribed and over the counter (OTC)) for rhinitis customized for 15 countries. Results: A total of 2871 users filled in 17 091 days of VAS in 2015 and 2016. Medications were reported for 9634 days. The assessment of days appeared to be more informative than the course of the treatment as, in real life, patients do not necessarily use treatment on a daily basis; rather, they appear to increase treatment use with the loss of symptom control. The Allergy Diary allowed differentiation between treatments within or between classes (intranasal corticosteroid use containing medications and oral H1-antihistamines). The control of days differed between no [best control], single, or multiple treatments (worst control). Conclusions: This study confirms the usefulness of the Allergy Diary in accessing and assessing everyday use and practice in AR. This pilot observational study uses a very simple assessment (VAS) on a mobile phone, shows novel findings, and generates new hypotheses. © 2018 EAACI and John Wiley and Sons A/S. Published by John Wiley and Sons Ltd.
  • No Thumbnail Available
    Item
    Mobile technology offers novel insights into the control and treatment of allergic rhinitis: The MASK study
    (Mosby Inc., 2019) Bédard A.; Basagaña X.; Anto J.M.; Garcia-Aymerich J.; Devillier P.; Arnavielhe S.; Bedbrook A.; Onorato G.L.; Czarlewski W.; Murray R.; Almeida R.; Fonseca J.; Costa E.; Malva J.; Morais-Almeida M.; Pereira A.M.; Todo-Bom A.; Menditto E.; Stellato C.; Ventura M.T.; Cruz A.A.; Stelmach R.; da Silva J.; Larenas-Linnemann D.; Fuentes-Pérez J.M.; Huerta-Villalobos Y.R.; Emuzyte R.; Kvedariene V.; Valiulis A.; Kuna P.; Samolinski B.; Klimek L.; Mösges R.; Pfaar O.; Shamai S.; Annesi-Maesano I.; Bosse I.; Demoly P.; Fontaine J.-F.; Cardona V.; Mullol J.; Valero A.; Roller-Wirnsberger R.E.; Tomazic P.V.; Chavannes N.H.; Fokkens W.J.; Reitsma S.; Bewick M.; Ryan D.; Sheikh A.; Haahtela T.; Toppila-Salmi S.; Valovirta E.; Makris M.; Papadopoulos N.G.; Prokopakis E.P.; Psarros F.; Cingi C.; Gemicioğlu B.; Yorgancioglu A.; Bosnic-Anticevich S.; O'Hehir R.E.; Bachert C.; Hellings P.W.; Pugin B.; Bindslev-Jensen C.; Eller E.; Kull I.; Melén E.; Wickman M.; De Vries G.; van Eerd M.; Agache I.; Ansotegui I.J.; Dykewicz M.S.; Casale T.; Wallace D.; Waserman S.; Laune D.; Bousquet J.
    Background: Mobile health can be used to generate innovative insights into optimizing treatment to improve allergic rhinitis (AR) control. Objectives: A cross-sectional real-world observational study was undertaken in 22 countries to complement a pilot study and provide novel information on medication use, disease control, and work productivity in the everyday life of patients with AR. Methods: A mobile phone app (Allergy Diary, which is freely available on Google Play and Apple stores) was used to collect the data of daily visual analogue scale (VAS) scores for (1) overall allergic symptoms; (2) nasal, ocular, and asthma symptoms; (3) work; and (4) medication use by using a treatment scroll list including all allergy medications (prescribed and over-the-counter) customized for 22 countries. The 4 most common intranasal medications containing intranasal corticosteroids and 8 oral H1-antihistamines were studied. Results: Nine thousand one hundred twenty-two users filled in 112,054 days of VASs in 2016 and 2017. Assessment of days was informative. Control of days with rhinitis differed between no (best control), single (good control for intranasal corticosteroid–treated days), or multiple (worst control) treatments. Users with the worst control increased the range of treatments being used. The same trend was found for asthma, eye symptoms, and work productivity. Differences between oral H1-antihistamines were found. Conclusions: This study confirms the usefulness of the Allergy Diary in accessing and assessing behavior in patients with AR. This observational study using a very simple assessment tool (VAS) on a mobile phone had the potential to answer questions previously thought infeasible. © 2019 American Academy of Allergy, Asthma & Immunology
  • No Thumbnail Available
    Item
    Asthma and rhinitis control in adolescents and young adults: A real-world MASK-air study
    (John Wiley and Sons Inc, 2024) Sousa-Pinto B.; Valiulis A.; Melén E.; Koppelman G.H.; Papadopoulos N.G.; Makela M.; Haahtela T.; Bonini M.; Braido F.; Brussino L.; Cruz A.A.; Fiocchi A.; Giovannini M.; Gemicioglu B.; Kulus M.; Kuna P.; Kupczyk M.; Kvedariene V.; Larenas-Linnemann D.E.; Louis R.; Morais-Almeida M.; Niedoszytko M.; Ollert M.; Pfaar O.; Regateiro F.S.; Roberts G.; Samolinski B.; Savouré M.; Taborda-Barata L.; Toppila-Salmi S.; Ventura M.T.; Vazquez-Ortiz M.; Vieira R.J.; Fonseca J.A.; Yorgancioglu A.; Zuberbier T.; Anto J.M.; Bousquet J.; Pham-Thi N.
    Background: In allergic rhinitis and asthma, adolescents and young adult patients are likely to differ from older patients. We compared adolescents, young adults and adults on symptoms, control levels, and medication adherence. Methods: In a cross-sectional study (2015–2022), we assessed European users of the MASK-air mHealth app of three age groups: adolescents (13–18 years), young adults (18–26 years), and adults (>26 years). We compared them on their reported rhinitis and asthma symptoms, use and adherence to rhinitis and asthma treatment and app adherence. Allergy symptoms and control were assessed by means of visual analogue scales (VASs) on rhinitis or asthma, the combined symptom-medication score (CSMS), and the electronic daily control score for asthma (e-DASTHMA). We built multivariable regression models to compare symptoms or medication accounting for potential differences in demographic characteristics and baseline severity. Results: We assessed 965 adolescent users (15,252 days), 4595 young adults (58,161 days), and 15,154 adult users (258,796 days). Users of all three age groups displayed similar app adherence. In multivariable models, age groups were not found to significantly differ in their adherence to rhinitis or asthma medication. These models also found that adolescents reported lower VAS on global allergy, ocular, and asthma symptoms (as well as lower CSMS) than young adults and adults. Conclusions: Adolescents reported a better rhinitis and asthma control than young adults and adults, even though similar medication adherence levels were observed across age groups. These results pave the way for future studies on understanding how adolescents control their allergic diseases. © 2024 The Authors. Pediatric Allergy and Immunology published by European Academy of Allergy and Clinical Immunology and John Wiley & Sons Ltd.